Cell Source, Inc.: directors' dealings · United States · SEC (Form 4)

About Cell Source, Inc.

Cell Source, Inc. (ticker CLCS) is a United States biotechnology company focused on immune-tolerance-based cell therapy. Based on the most recent verifiable public disclosures, it is not currently a NYSE/NASDAQ-listed operating company; the stock has been quoted in the OTC market. The company was incorporated in Nevada on June 6, 2012, and its operating subsidiary, Cell Source Limited, was founded in Israel in 2011 to commercialize a suite of inventions related to cancer treatments. Public filings and company materials also show a strong Israel-linked scientific footprint, including historical headquarters references in Tel Aviv, while the parent company remains a U.S. legal entity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1569340/000149315224024903/form10-k.htm?utm_source=openai)) Cell Source’s core business is the development of cell-therapy products that manage immune tolerance. Its lead platform is the patented Veto Cell technology, which is designed to selectively block immune responses and thereby improve the feasibility of advanced therapies. The company describes its technology as applicable to hematologic cancers and transplant medicine, with target areas including leukemia, lymphoma, multiple myeloma, stem-cell transplant acceptance, and organ-transplant tolerance. In investor terms, this is an early-stage, high-risk, high-upside biotech story rather than a commercial revenue platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1569340/000149315224024903/form10-k.htm?utm_source=openai)) From a competitive standpoint, Cell Source operates in a crowded but highly innovative cell-therapy landscape. Its differentiation lies in the “Veto Cell” approach, which aims to support durable immune tolerance and potentially enable allogeneic or off-the-shelf applications. The company has communicated that its therapeutic concept combines cancer-targeting functionality with persistence and protection from immune rejection, a positioning that is relevant in the CAR-T and transplant markets. That said, it remains materially smaller and earlier than the leading commercial cell-therapy players, and its long-term value creation will depend on clinical validation, regulatory progress, and successful funding execution. ([cell-source.com](https://cell-source.com/?utm_source=openai)) Geographically, Cell Source is a cross-border biotech: a U.S.-incorporated company with research roots and licensing relationships in Israel. A key part of its intellectual-property position comes from a research and license agreement with Yeda, the technology transfer arm of the Weizmann Institute of Science in Israel. The company also highlights clinical work associated with MD Anderson Cancer Center in Texas, which gives it a U.S. clinical-development footprint alongside its Israeli scientific base. For investors in the U.S., Europe, and Switzerland, this combination can be attractive because it offers access to both Israeli biotech innovation and U.S.-based oncology research infrastructure. ([yedarnd.com](https://www.yedarnd.com/cell-source?utm_source=openai)) Recent developments have been encouraging on the scientific side. Cell Source reported positive interim results from a Phase 1/2 first-in-human clinical trial conducted at MD Anderson Cancer Center, and it also presented data related to an off-the-shelf CAR-T concept at an American Society of Hematology meeting. These announcements support the view that the company is moving its platform through early clinical translation, but they do not yet establish commercial traction. In practical terms, CLCS should still be viewed as a speculative clinical-stage biotech whose share performance is likely to be driven by trial updates, intellectual-property news, financing events, and broader sentiment toward cell therapy. ([nasdaq.com](https://www.nasdaq.com/press-release/cell-source-shares-promising-interim-results-groundbreaking-veto-cell-clinical-trial?utm_source=openai))